Tobacco use in the Myeloproliferative neoplasms: symptom burden, patient opinions, and care

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Tobacco use in the Myeloproliferative neoplasms : symptom burden, patient opinions, and care. / Christensen, Sarah F.; Scherber, Robyn M.; Mazza, Gina L.; Dueck, Amylou C.; Brochmann, Nana; Andersen, Christen L.; Hasselbalch, Hans C.; Mesa, Ruben A.; Geyer, Holly L.

In: BMC Cancer, Vol. 21, No. 1, 691, 2021.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Christensen, SF, Scherber, RM, Mazza, GL, Dueck, AC, Brochmann, N, Andersen, CL, Hasselbalch, HC, Mesa, RA & Geyer, HL 2021, 'Tobacco use in the Myeloproliferative neoplasms: symptom burden, patient opinions, and care', BMC Cancer, vol. 21, no. 1, 691. https://doi.org/10.1186/s12885-021-08439-7

APA

Christensen, S. F., Scherber, R. M., Mazza, G. L., Dueck, A. C., Brochmann, N., Andersen, C. L., Hasselbalch, H. C., Mesa, R. A., & Geyer, H. L. (2021). Tobacco use in the Myeloproliferative neoplasms: symptom burden, patient opinions, and care. BMC Cancer, 21(1), [691]. https://doi.org/10.1186/s12885-021-08439-7

Vancouver

Christensen SF, Scherber RM, Mazza GL, Dueck AC, Brochmann N, Andersen CL et al. Tobacco use in the Myeloproliferative neoplasms: symptom burden, patient opinions, and care. BMC Cancer. 2021;21(1). 691. https://doi.org/10.1186/s12885-021-08439-7

Author

Christensen, Sarah F. ; Scherber, Robyn M. ; Mazza, Gina L. ; Dueck, Amylou C. ; Brochmann, Nana ; Andersen, Christen L. ; Hasselbalch, Hans C. ; Mesa, Ruben A. ; Geyer, Holly L. / Tobacco use in the Myeloproliferative neoplasms : symptom burden, patient opinions, and care. In: BMC Cancer. 2021 ; Vol. 21, No. 1.

Bibtex

@article{b694b3a887be44f99be45a7f62c524bd,
title = "Tobacco use in the Myeloproliferative neoplasms: symptom burden, patient opinions, and care",
abstract = "Background: Patients with Philadelphia-negative Myeloproliferative Neoplasms (MPN) suffer from numerous symptoms and decreased quality of life. Smoking is associated with an increased symptom burden in several malignancies. The aim of this study was to analyze the association between smoking and MPN-related symptom burden and explore MPN patients{\textquoteright} opinions on smoking. Methods: A total of 435 patients with MPN participated in a cross-sectional internet-based survey developed by the Mayo Clinic and the Myeloproliferative Neoplasm Quality of Life Group. Patients reported their demographics, disease characteristics, tobacco use, and opinions on tobacco use. In addition, MPN-related symptoms were reported via the validated 10-item version of the Myeloproliferative Neoplasms Symptom Assessment Form. Results: Current/former smokers reported worse fatigue (mean severity 5.6 vs. 5.0, p = 0.02) and inactivity (mean severity 4.0 vs. 3.4, p = 0.03) than never smokers. Moreover, current/former smokers more frequently experienced early satiety (68.5% vs. 58.3%, p = 0.03), inactivity (79.9% vs. 71.1%, p = 0.04), and concentration difficulties (82.1% vs. 73.1%, p = 0.04). Although not significant, a higher total symptom burden was observed for current/former smokers (mean 30.4 vs. 27.0, p = 0.07). Accordingly, overall quality of life was significantly better among never smokers than current/former smokers (mean 3.5 vs. 3.9, p = 0.03). Only 43.2% of the current/former smokers reported having discussed tobacco use with their physician, and 17.5% did not believe smoking increased the risk of thrombosis. Conclusion: The current study suggests that smoking may be associated with increased prevalence and severity of MPN symptoms and underscores the need to enhance patient education and address tobacco use in the care of MPN patients.",
keywords = "Cross-sectional internet-based survey, Myeloproliferative neoplasms, Quality of life, Symptom burden, Tobacco use",
author = "Christensen, {Sarah F.} and Scherber, {Robyn M.} and Mazza, {Gina L.} and Dueck, {Amylou C.} and Nana Brochmann and Andersen, {Christen L.} and Hasselbalch, {Hans C.} and Mesa, {Ruben A.} and Geyer, {Holly L.}",
note = "Publisher Copyright: {\textcopyright} 2021, The Author(s).",
year = "2021",
doi = "10.1186/s12885-021-08439-7",
language = "English",
volume = "21",
journal = "B M C Cancer",
issn = "1471-2407",
publisher = "BioMed Central Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - Tobacco use in the Myeloproliferative neoplasms

T2 - symptom burden, patient opinions, and care

AU - Christensen, Sarah F.

AU - Scherber, Robyn M.

AU - Mazza, Gina L.

AU - Dueck, Amylou C.

AU - Brochmann, Nana

AU - Andersen, Christen L.

AU - Hasselbalch, Hans C.

AU - Mesa, Ruben A.

AU - Geyer, Holly L.

N1 - Publisher Copyright: © 2021, The Author(s).

PY - 2021

Y1 - 2021

N2 - Background: Patients with Philadelphia-negative Myeloproliferative Neoplasms (MPN) suffer from numerous symptoms and decreased quality of life. Smoking is associated with an increased symptom burden in several malignancies. The aim of this study was to analyze the association between smoking and MPN-related symptom burden and explore MPN patients’ opinions on smoking. Methods: A total of 435 patients with MPN participated in a cross-sectional internet-based survey developed by the Mayo Clinic and the Myeloproliferative Neoplasm Quality of Life Group. Patients reported their demographics, disease characteristics, tobacco use, and opinions on tobacco use. In addition, MPN-related symptoms were reported via the validated 10-item version of the Myeloproliferative Neoplasms Symptom Assessment Form. Results: Current/former smokers reported worse fatigue (mean severity 5.6 vs. 5.0, p = 0.02) and inactivity (mean severity 4.0 vs. 3.4, p = 0.03) than never smokers. Moreover, current/former smokers more frequently experienced early satiety (68.5% vs. 58.3%, p = 0.03), inactivity (79.9% vs. 71.1%, p = 0.04), and concentration difficulties (82.1% vs. 73.1%, p = 0.04). Although not significant, a higher total symptom burden was observed for current/former smokers (mean 30.4 vs. 27.0, p = 0.07). Accordingly, overall quality of life was significantly better among never smokers than current/former smokers (mean 3.5 vs. 3.9, p = 0.03). Only 43.2% of the current/former smokers reported having discussed tobacco use with their physician, and 17.5% did not believe smoking increased the risk of thrombosis. Conclusion: The current study suggests that smoking may be associated with increased prevalence and severity of MPN symptoms and underscores the need to enhance patient education and address tobacco use in the care of MPN patients.

AB - Background: Patients with Philadelphia-negative Myeloproliferative Neoplasms (MPN) suffer from numerous symptoms and decreased quality of life. Smoking is associated with an increased symptom burden in several malignancies. The aim of this study was to analyze the association between smoking and MPN-related symptom burden and explore MPN patients’ opinions on smoking. Methods: A total of 435 patients with MPN participated in a cross-sectional internet-based survey developed by the Mayo Clinic and the Myeloproliferative Neoplasm Quality of Life Group. Patients reported their demographics, disease characteristics, tobacco use, and opinions on tobacco use. In addition, MPN-related symptoms were reported via the validated 10-item version of the Myeloproliferative Neoplasms Symptom Assessment Form. Results: Current/former smokers reported worse fatigue (mean severity 5.6 vs. 5.0, p = 0.02) and inactivity (mean severity 4.0 vs. 3.4, p = 0.03) than never smokers. Moreover, current/former smokers more frequently experienced early satiety (68.5% vs. 58.3%, p = 0.03), inactivity (79.9% vs. 71.1%, p = 0.04), and concentration difficulties (82.1% vs. 73.1%, p = 0.04). Although not significant, a higher total symptom burden was observed for current/former smokers (mean 30.4 vs. 27.0, p = 0.07). Accordingly, overall quality of life was significantly better among never smokers than current/former smokers (mean 3.5 vs. 3.9, p = 0.03). Only 43.2% of the current/former smokers reported having discussed tobacco use with their physician, and 17.5% did not believe smoking increased the risk of thrombosis. Conclusion: The current study suggests that smoking may be associated with increased prevalence and severity of MPN symptoms and underscores the need to enhance patient education and address tobacco use in the care of MPN patients.

KW - Cross-sectional internet-based survey

KW - Myeloproliferative neoplasms

KW - Quality of life

KW - Symptom burden

KW - Tobacco use

U2 - 10.1186/s12885-021-08439-7

DO - 10.1186/s12885-021-08439-7

M3 - Journal article

C2 - 34112113

AN - SCOPUS:85107655278

VL - 21

JO - B M C Cancer

JF - B M C Cancer

SN - 1471-2407

IS - 1

M1 - 691

ER -

ID: 300379661